)
Adocia (ADOC) investor relations material
Adocia H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Operational revenue for H1 2026 was €1.3M, mainly from a feasibility study on BioChaperone® for a new peptide combination; prior year revenue was €2.2M, driven by AdOral® feasibility work.
Net loss improved to €8.6M from €9.3M year-over-year, reflecting lower operating expenses and stable R&D focus.
Cash position at June 30, 2026 was €9.7M, down from €17.2M at year-end 2025, with a cash runway into early Q2 2027, assuming full use of a new shareholder loan facility.
Significant progress in clinical and preclinical programs, including positive Phase 3 results for BioChaperone® Lispro in China and new platform developments.
Board of Directors refreshed with new Chairman, two new Directors, and a Board Observer.
Financial highlights
Revenue: €1.3M for H1 2026 vs. €2.2M in H1 2025; main revenue from feasibility studies and research tax credit.
Operating expenses: €9.3M, down €1.8M year-over-year, mainly due to lower IFRS 2 charges, FX impacts, and personnel costs.
Net loss: €8.6M for H1 2026, improved from €9.3M in H1 2025.
Cash burn for H1 2026 was €10.1M, compared to €11.8M in H1 2025.
Net financial debt (excluding IFRS 16): €1.8M at June 30, 2026, including €0.7M in state-guaranteed loans (fully repaid by August 2026) and €0.7M in shareholder advances.
Outlook and guidance
Cash runway extends to early Q2 2027, contingent on full drawdown of the Vester Finance facility and no new partnership revenue.
Significant uncertainty remains regarding ability to continue operations beyond this period without additional funding.
Active efforts underway to secure further financing and strategic partnerships while reducing costs.
- Revenue up, net loss down, and cash runway extended to Q2 2026 with major clinical milestones ahead.ADOC
H2 2024 - Strong cash position and positive R&D progress support strategic focus on BioChaperone®.ADOC
Q2 2026 TU - Innovative peptide platforms drive growth in diabetes and obesity therapeutics.ADOC
Investor presentation - BC Lispro/BCLIS achieved superior postprandial and daily glucose control with non-inferior HbA1c.ADOC
Study result - Cash runway secured to Q2 2027; BioChaperone® prioritized after positive study results.ADOC
Q1 2026 TU - Pipeline advances and new financing extend cash runway to Q2 2027 despite wider net loss.ADOC
H2 2025 - Strong clinical progress, robust cash, and leadership changes mark a transformative quarter.ADOC
Q4 2025 TU - H1 2025 saw higher revenue and cash inflow, but net loss increased to €9.3 million.ADOC
H1 2025 - Net loss €8.9M, €10.3M cash, funding to Q3 2025, key programs advancing.ADOC
H1 2024
Next Adocia earnings date
Next Adocia earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)